Plain-English translation of NCT06647498 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing , a new medication designed to slow the buildup of harmful proteins in the brain associated with Alzheimer's disease. The study focuses on people who carry specific genetic mutations known to cause early-onset Alzheimer's but who don't yet have any memory or thinking problems. By treating people before symptoms appear, researchers hope to delay or prevent the disease from developing.
Alzheimer's disease develops silently in the brain for many years before memory loss appears. Research suggests that treating people early—before symptoms start—offers the best chance to slow the disease. This medication is being tested to see if it can stop harmful protein buildup in the brain during these early, asymptomatic stages.
You likely qualify if…
You likely don't qualify if…
The study has two stages. In Stage 1, you will be randomly assigned to receive either the new medication or a placebo (inactive treatment) in a blinded format, meaning you won't know which one you're getting. You'll have regular visits to take the medication, complete thinking and memory tests, and have brain imaging scans to track changes. After Stage 1 ends, eligible participants move to Stage 2, where everyone receives the open-label medication (meaning you'll know you're getting the active treatment). Throughout the trial, you'll work closely with your study partner to help track any changes in your thinking or daily activities.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
United States